Micronized Eggshell Membrane Particles Control MMPs in Chronic Wounds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional wound healing treatments fail to address the imbalance in the wound repair cycle, particularly the inflammatory and tissue remodeling stages of chronic wounds, leading to excessive MMP activity and inflammatory responses that degrade ECM proteins and growth factors, and lack a non-mammalian source for effective treatment.
Innovation Solution
Micronized eggshell membrane (ESM) particles with a mean diameter of less than 100 μm are applied to chronic wounds to reduce MMP activity, promote tissue formation, and control inflammation, providing a non-mammalian source for wound healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional wound healing treatments are used, then the basic wound care is provided, but the imbalance in wound repair cycle is not addressed, leading to excessive MMP activity and inflammatory responses
Solution Approach 1:
The patent applies eggshell membrane particles that contain natural inhibitors which convert the harmful excessive MMP activity and inflammatory response into beneficial controlled healing. The membrane particles are applied to the wound bed to suppress harmful MMP activity and reduce excessive inflammation, transforming the pathological state into a healing-promoting environment.
2Adaptability or versatility
If conventional treatments are used, then basic care is provided, but there is lack of non-mammalian source for effective treatment
Solution Approach 1:
The patent utilizes eggshell membrane, a readily available and cost-effective material from avian sources, to create disposable microparticles for wound treatment. These particles are applied topically to the wound and provide effective treatment without requiring mammalian-derived products, thus diversifying the treatment source while maintaining reliability.
3Reliability
If micronized ESM particles are applied, then MMP activity is reduced and tissue formation is promoted, but the particle size must be precisely controlled
Solution Approach 1:
The patent specifies that eggshell membrane particles should have a mean diameter of less than 100 μm to achieve optimal wound healing effects. This parameter control ensures that the particles can effectively reduce MMP activity and promote tissue formation while being manageable for clinical application. The micronization process transforms the membrane into fine particles with controlled size distribution.
Data Source
AI summary
Provided herein is a particle consisting essentially of micronized ESM and having a mean particle diameter of less than 100 μm for use in promoting the healing of a chronic wound at risk of, or in which there is, (i) an inappropriate level of matrix-metalloproteinase (MMP) activity against extracellular matrix (ECM) proteins and/or peptide growth or differentiation factors, and/or (ii) an excessive inflammatory response. Further provided are pharmaceutical compositions, wound dressings and implantable medical devices including the micronized ESM-containing particles for use in said treatments. Still further provided are methods for manufacturing the micronized ESM-containing particles and the compositions, dressings and implantable medical devices including the same.